Companies › Kadence Bio
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KH-001 besylate | – | Phase 2 | Premature Ejaculation | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07434271 | KH-001 besylate | Phase 2 | Premature Ejaculation | Psychiatry | Nov 2026 |
No annotated target.
–
Draig Therapeutics HB BioTech Beckley Psytech Synendos Therapeutics Neuroventi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.